4/15
04:23 pm
prta
Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma [Yahoo! Finance]
Low
Report
Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma [Yahoo! Finance]
4/15
04:05 pm
prta
Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
Low
Report
Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
4/10
02:14 pm
prta
Prothena Co. plc (NASDAQ: PRTA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
Prothena Co. plc (NASDAQ: PRTA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
3/18
03:15 pm
prta
Prothena Co. plc (NASDAQ: PRTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Low
Report
Prothena Co. plc (NASDAQ: PRTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
3/5
04:05 pm
prta
Prothena to Participate in Upcoming Healthcare Conferences
Medium
Report
Prothena to Participate in Upcoming Healthcare Conferences
3/4
04:22 pm
prta
Prothena Appoints David Ford to Newly Created Chief People Officer Position [Yahoo! Finance]
Low
Report
Prothena Appoints David Ford to Newly Created Chief People Officer Position [Yahoo! Finance]
3/4
04:05 pm
prta
Prothena Appoints David Ford to Newly Created Chief People Officer Position
Low
Report
Prothena Appoints David Ford to Newly Created Chief People Officer Position
2/21
04:18 pm
prta
Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate [Yahoo! Finance]
Low
Report
Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate [Yahoo! Finance]
2/21
04:05 pm
prta
Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate
Low
Report
Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate
2/20
09:15 am
prta
Prothena Co. plc (NASDAQ: PRTA) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $98.00 to $80.00. They now have an "outperform" rating on the stock.
Low
Report
Prothena Co. plc (NASDAQ: PRTA) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $98.00 to $80.00. They now have an "outperform" rating on the stock.
2/19
11:04 pm
prta
Prothena Co. plc (NASDAQ: PRTA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Prothena Co. plc (NASDAQ: PRTA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
2/16
03:40 pm
prta
Prothena Co. plc (NASDAQ: PRTA) had its price target raised by analysts at JMP Securities from $81.00 to $85.00. They now have a "market outperform" rating on the stock.
Low
Report
Prothena Co. plc (NASDAQ: PRTA) had its price target raised by analysts at JMP Securities from $81.00 to $85.00. They now have a "market outperform" rating on the stock.
2/16
03:13 pm
prta
Prothena (PRTA) Q4 Earnings Miss Estimates on Higher R&D Expense [Yahoo! Finance]
Neutral
Report
Prothena (PRTA) Q4 Earnings Miss Estimates on Higher R&D Expense [Yahoo! Finance]
2/16
01:36 pm
prta
Prothena Co. plc (NASDAQ: PRTA) had its price target lowered by analysts at Royal Bank of Canada from $36.00 to $35.00. They now have a "sector perform" rating on the stock.
Low
Report
Prothena Co. plc (NASDAQ: PRTA) had its price target lowered by analysts at Royal Bank of Canada from $36.00 to $35.00. They now have a "sector perform" rating on the stock.
2/16
10:53 am
prta
Prothena Corporation plc (NASDAQ:PRTA) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Prothena Corporation plc (NASDAQ:PRTA) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
2/15
04:14 pm
prta
Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights [Yahoo! Finance]
Low
Report
Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights [Yahoo! Finance]
2/15
04:05 pm
prta
Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights
Low
Report
Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights
2/14
06:21 am
prta
Inside the plan to diagnose Alzheimer's in people with no memory problems — and who stands to benefit [Yahoo! Finance]
Low
Report
Inside the plan to diagnose Alzheimer's in people with no memory problems — and who stands to benefit [Yahoo! Finance]
2/14
06:02 am
prta
Inside the plan to diagnose Alzheimer's in people with no memory problems — and who stands to benefit [Los Angeles Times (CA)]
Low
Report
Inside the plan to diagnose Alzheimer's in people with no memory problems — and who stands to benefit [Los Angeles Times (CA)]
2/8
04:24 pm
prta
Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024 [Yahoo! Finance]
Medium
Report
Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024 [Yahoo! Finance]
2/8
04:05 pm
prta
Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024
Medium
Report
Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024
1/30
08:06 am
prta
Prothena Co. plc (NASDAQ: PRTA) had its "neutral" rating re-affirmed by analysts at Bank of America Co.. They now have a $38.00 price target on the stock, down previously from $68.00.
Medium
Report
Prothena Co. plc (NASDAQ: PRTA) had its "neutral" rating re-affirmed by analysts at Bank of America Co.. They now have a $38.00 price target on the stock, down previously from $68.00.
1/25
11:59 am
prta
Prothena Co. plc (NASDAQ: PRTA) had its price target lowered by analysts at Royal Bank of Canada from $43.00 to $36.00. They now have a "sector perform" rating on the stock.
Low
Report
Prothena Co. plc (NASDAQ: PRTA) had its price target lowered by analysts at Royal Bank of Canada from $43.00 to $36.00. They now have a "sector perform" rating on the stock.